Statin use and functional outcome after tissue plasminogen activator treatment in acute ischaemic stroke

Cerebrovascular Diseases

Volumn 29, Issue 3, 2010, Pages 263-267

  Miedema, I ^a   Uyttenboogaart, M ^a   Koopman, K ^a   De Keyser, J ^b   Luijckx, G J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

Acute ischaemic stroke; Statins; Tissue plasminogen activator

Indexed keywords

ANTITHROMBOCYTIC AGENT; CHOLESTEROL; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG USE; FEMALE; FUNCTIONAL STATUS; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANKIN SCALE; RISK FACTOR; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; CHI-SQUARE DISTRIBUTION; DATABASES AS TOPIC; DISABILITY EVALUATION; FEMALE; FIBRINOLYTIC AGENTS; HOSPITAL MORTALITY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTRACRANIAL HEMORRHAGES; LOGISTIC MODELS; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; ODDS RATIO; PROSPECTIVE STUDIES; RECOVERY OF FUNCTION; RISK ASSESSMENT; RISK FACTORS; STROKE; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 74249096973     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000275500     Document Type: Article

References (21)

1. Amarenco P, Benavente O, Goldstein LB, Callahan A III, Sillesen H, Hennerici MG, et al.: Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes. Stroke 2009; 40: 1405-1409.
2. Alvarez-Sabin J, Huertas R, Quintana M, Rubiera M, Delgado P, Ribo M, et al.: Prior statin use may be associated with improved stroke outcome after tissue plasminogen activator. Stroke 2007; 38: 1076-1078.
3. Greisenegger S, Mullner M, Tentschert S, Lang W, Lalouschek W: Effect of pretreatment with statins on the severity of acute ischemic cerebrovascular events. J Neurol Sci 2004; 221: 5-10.
4. Jonsson N, Asplund K: Does pretreatment with statins improve clinical outcome after stroke? A pilot case-referent study. Stroke 2001; 32: 1112-1115.
5. Marti-Fabregas J, Gomis M, Arboix A, Aleu A, Pagonabarraga J, Belvis R, et al.: Favorable outcome of ischemic stroke in patients pretreated with statins. Stroke 2004; 35: 1117-1121.
6. Yoon SS, Dambrosia J, Chalela J, Ezzeddine M, Warach S, Haymore J, et al.: Rising statin use and effect on ischemic stroke outcome. BMC Med 2004; 2: 4.
7. Fuentes B, Martinez-Sanchez P, Diez-Tejedor E: Lipid-lowering drugs in ischemic stroke prevention and their influence on acute stroke outcome. Cerebrovasc Dis 2009; 27(suppl 1):126-133.
8. Chen J, Zhang ZG, Li Y, Wang Y, Wang L, Jiang H, et al.: Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol 2003; 53: 743-751.
9. Kawashima S, Yamashita T, Miwa Y, Ozaki M, Namiki M, Hirase T, et al.: HMG-CoA reductase inhibitor has protective effects against stroke events in stroke-prone spontaneously hypertensive rats. Stroke 2003; 34: 157-163.
10. Vaughan CJ, Delanty N: Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke 1999; 30: 1969-1973.
11. Martinez-Sanchez P, Rivera-Ordonez C, Fuentes B, Ortega-Casarrubios MA, Idrovo L, Diez-Tejedor E: The beneficial effect of statins treatment by stroke subtype. Eur J Neurol 2009; 16: 127-133.
12. Amarenco P, Labreuche J, Elbaz A, Touboul PJ, Driss F, Jaillard A, et al.: Blood lipids in brain infarction subtypes. Cerebrovasc Dis 2006; 22: 101-108.
13. Bang OY, Saver JL, Liebeskind DS, Starkman S, Villablanca P, Salamon N, et al.: Cholesterol level and symptomatic hemorrhagic transformation after ischemic stroke thrombolysis. Neurology 2007; 68: 737-742.
14. Uyttenboogaart M, Vroomen PC, Stewart RE, De Keyser J, Luijckx GJ: Safety of routine IV thrombolysis between 3 and 4.5 h after ischemic stroke. J Neurol Sci 2007; 254: 28-32.
15. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al.: Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24: 35-41.
16. Wahlgren N, Ahmed N, Davalos A, Ford GA, Grond M, Hacke W, et al.: Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007; 369: 275-282.
17. Uyttenboogaart M, Koch MW, Koopman K, Vroomen PC, Luijckx GJ, De Keyser J: Lipid profile, statin use, and outcome after intravenous thrombolysis for acute ischaemic stroke. J Neurol 2008; 255: 875-880.
18. Wang S, Lee SR, Guo SZ, Kim WJ, Montaner J, Wang X, et al.: Reduction of tissue plasminogen activator-induced matrix metalloproteinase-9 by simvastatin in astrocytes. Stroke 2006; 37: 1910-1912.
19. Rosenson RS, Tangney CC: Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998; 279: 1643-1650.
20. Prinz V, Laufs U, Gertz K, Kronenberg G, Balkaya M, Leithner C, et al.: Intravenous rosuvastatin for acute stroke treatment: an animal study. Stroke 2008; 39: 433-438.
21. Blanco M, Nombela F, Castellanos M, Rodriguez- Yanez M, Garcia-Gil M, Leira R, et al.: Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology 2007; 69: 904-910.